# PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
SYNGENTA LIMITED	02/26/2009

### **RECEIVING PARTY DATA**

Name:	ASTRAZENECA UK LTD	
Street Address:	15 STANHOPE GATE	
City:	LONDON	
State/Country:	UNITED KINGDOM	
Postal Code:	W1K 1LN	

#### PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	09983543

# **CORRESPONDENCE DATA**

Fax Number: (202)824-3751

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 2028243000

Email: SKAGAN@BANNERWITCOFF.COM

Correspondent Name: SARAH A KAGAN

Address Line 1: 1100 13TH STREET, NW

Address Line 2: SUITE 1200

Address Line 4: WASHINGTON, DISTRICT OF COLUMBIA 20005

ATTORNEY DOCKET NUMBER: 001107.00206

NAME OF SUBMITTER: SARAH A. KAGAN

Total Attachments: 2

source=syngentaAZassignmentexec#page1.tif source=syngentaAZassignmentexec#page2.tif

PATENT

09983

:H \$40.00

# <u>ASSIGNMENT</u>

WHEREAS, SYNGENTA LIMITED, a corporation organized and existing by virtue of the laws of England and Wales, having its principal place of business at Syngenta European Regional Centre, Priestley Road, Surrey Research Park, Guildford, Surrey GU2 7YH, is the assignee and owner of APC Antibodies (hereinafter referred to as the "Invention"), filed on October 24, 2001 and assigned Serial No. 09/983543 by the U.S. Patent and Trademark Office (hereinafter referred to as the "Patent Application"); and

WHEREAS, AstraZeneca UK LTD., a corporation organized and existing by virtue of the laws of England and Wales, having a registered office at 15 Stanhope Gate, London W1K 1LN, is desirous of acquiring an interest in said Invention and said Patent Application;

NOW, THEREFORE, SYNGENTA LIMITED for good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, by these presents does assign and transfer to AstraZeneca UK LTD., its successors and assigns, the entire right, title, and interest in and to said Invention and Patent Application, including the right to bring suit or other judicial or administrative action against any third party for infringement of same occurring at any time, including without limitations any infringement occurring prior to the date hereof, and to recover and retain for itself damages for any such infringement, and the right to file continuations, divisions, reissues, extensions, and renewals thereof and the like in AstraZeneca UK LTD.'s own name based on or corresponding to the Patent Application, along with the right of priority to the filing date of the Patent Application, and any and all Letters Patent and utility model patents and the like which may now or hereafter be granted on the Patent Application or on any and all continuations, divisions, reissues, extensions, and renewals thereof and the like.

AND, SYNGENTA LIMITED does hereby further covenant and agree that it will, without further consideration, communicate with AstraZeneca UK LTD, or with its successors or assigns, any facts known to SYNGENTA LIMITED respecting said Invention or the Patent Application, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all

PATENT REEL: 022315 FRAME: 0561 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

001107.00206

papers that may be necessary or desirable to perfect the title to the said Invention or the Patent Application in AstraZeneca UK LTD. or its successors or assigns, execute all provisional, non-provisional, divisional, continuation, continuation-in-part and reissue applications, make all rightful oaths and generally do everything possible to aid AstraZeneca UK LTD. or its successors or assigns, to obtain and enforce proper patent protection for the said inventions in any country, it being understood that any expense incident to the execution of such papers shall be borne by AstraZeneca UK LTD. or its successors or assigns.

This Assignment is executed the 26 H. day of Ebruary, 2009.

SYNGENTA LIMITED

RECORDED: 02/26/2009

Signature:

By: JOHN RICHARD MACK

Title: AUTHORISED SIGNATORY

OR Mack

Date: FEBRUARY 26 2009